The use of array-CGH in a cohort of Greek children with developmental delay by Manolakos, Emmanouil et al.
RESEARCH Open Access
The use of array-CGH in a cohort of Greek
children with developmental delay
Emmanouil Manolakos
1,11*, Annalisa Vetro
2, Konstantinos Kefalas
1, Stamatia-Maria Rapti
1, Eirini Louizou
1,
Antonios Garas
3, George Kitsos
4, Lefteris Vasileiadis
5, Panagiota Tsoplou
1, Makarios Eleftheriades
6,
Panagiotis Peitsidis
7, Sandro Orru
8, Thomas Liehr
9, Michael B Petersen
10, Loretta Thomaidis
11
Abstract
Background: The genetic diagnosis of mental retardation (MR) is difficult to establish and at present many cases
remain undiagnosed and unexplained. Standard karyotyping has been used as one of the routine techniques for
the last decades. The implementation of Array Comparative Genomic Hybridization (array-CGH) has enabled the
analysis of copy number variants (CNVs) with high resolution. Major cohort studies attribute 11% of patients with
unexplained mental retardation to clinically significant CNVs. Here we report the use of array-CGH for the first time
in a Greek cohort. A total of 82 children of Greek origin with mean age 4.9 years were analysed in the present
study. Patients with visible cytogenetic abnormalities ascertained by standard karyotyping as well as those with
subtelomeric abnormalities determined by Multiplex Ligation-dependent Probe Amplification (MLPA) or
subtelomeric FISH had been excluded.
Results: Fourteen CNVs were detected in the studied patients. In nine patients (11%) the chromosomal aberrations
were inherited from one of the parents. One patients showed two duplications, a 550 kb duplication in 3p14.1
inherited from the father and a ~1.1 Mb duplication in (22)(q13.1q13.2) inherited from the mother. Although both
parents were phenotypically normal, it cannot be excluded that the dual duplication is causative for the patient’s
clinical profile including dysmorphic features and severe developmental delay. Furthermore, three de novo clinically
significant CNVs were detected (3.7%). There was a ~6 Mb triplication of 18q21.1 in a girl 5 years of age with
moderate MR and mild dysmorphic features and a ~4.8 Mb duplication at (10)(q11.1q11.21) in a 2 years old boy
with severe MR, multiple congenital anomalies, severe central hypotonia, and ataxia. Finally, in a 3 year-old girl with
microcephaly and severe hypotonia a deletion in (2)(q31.2q31.3) of about ~3.9 Mb was discovered. All CNVs were
confirmed by Fluorescence in situ hybridization (FISH). For the remaining 9 patients the detected CNVs (inherited
duplications or deletions of 80 kb to 800 kb in size) were probably not associated with the clinical findings.
Conclusions: Genomic microarrays have within the recent years proven to be a highly useful tool in the
investigation of unexplained MR. The cohorts reported so far agree on an around 11% diagnostic yield of clinically
significant CNVs in patients with unexplained MR. Various publicly available databases have been created for the
interpretation of identified CNVs and parents are analyzed in case a rare CNV is identified in the child. We have
conducted a study of Greek patients with unexplained MR and confirmed the high diagnostic value of the
previous studies. It is important that the technique becomes available also in less developed countries when the
cost of consumables will be reduced.
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Mental retardation (MR) is a common disorder for which
the genetic diagnosis in many instances is lacking. The
detection rate of chromosomal abnormalities in patients
with MR and dysmorphic features has increased due to
the improvements of molecular cytogenetic methods.
Standard cytogenetic methods cannot detect imbalances
smaller than 5-10 Mb and the detection rate of visible
chromosomal abnormalities in patients with moderate to
severe MR is 3.7% [1]. The development of Fluorescence
in situ hybridization (FISH) probes for the subtelomeric
regions has led to the identification of cryptic unbalanced
rearrangements in an additional 2.5-3% of patients with
moderate/severe MR of unknown cause [2-4].
Molecular karyotyping (MK) through array-CGH or Sin-
gle Nucleotide Polymorphisms array (SNP-array) is rapidly
becoming the first tier clinical genetic test for patients
with unexplained developmental delay/intellectual disabil-
ity, autism spectrum disorders, and multiple congenital
anomalies. Numerous studies have clearly demonstrated
that MK offers a much higher diagnostic yield (15%-20%)
for this group of patients in respect to conventional karyo-
typing with a G-banded karyotype (approximately 3%,
excluding Down syndrome and other recognizable chro-
mosomal syndromes), primarily because of its higher sen-
sitivity for submicroscopic deletions and duplications [5].
The widespread application of this technique has lead
to the identification of large-scale copy number poly-
morphisms (CNPs), shown to contribute substantially to
genomic variation [6,7], and segmental duplications
were found to define hotspots of chromosomal rearran-
gements [8].
Here we report the first Greek experience from a
cohort of 82 children with learning disabilities and dys-
morphism, in whom subtelomeric chromosomal abnorm-
alities were excluded by FISH or MLPA techniques. All
children presented with various degrees of unexplained
MR or learning difficulties (MR/LD) and facial dys-
morphism/congenital malformations, suggestive of chro-
mosomal anomalies: a) not associated with congenital
brain malformation (CBM) in either CT or MRI brain
scan, b) associated with CBM in either CT or MRI brain
scan without improvement and c) associated with CBM
in either CT or MRI brain scan with improvement.
Results
Eighty-two patients with unexplained MR and presence
of features suggestive of a chromosomal anomaly were
analyzed by array-CGH. All patients had an apparently
normal karyotype when investigated by standard GTG-
banding (> 550 band resolution per haploid karyotype).
In addition, subtelomeric FISH and MLPA analyses
were performed without revealing any rearrangements.
Among the 82 patients analyzed, 13 (15.8%) were found
to have cryptic chromosomal imbalances: 6 patients
with duplications, 5 patients with deletions, one with tri-
plication and one patient with two duplications. Array-
CGH results and phenotype of these individuals are
given in Table 1. For all 13 patients, array-CGH analysis
has been extended to parental samples, so to establish if
an aberration was inherited or de novo. In 3 out of the
13 patients the chromosomal rearrangements occurred
de novo; these aberrations were classified as causative
for the phenotype. The other 11 aberrations which were
observed in the remaining of 10 patients, were consid-
ered as likely benign since they have not previously
been reported and have been inherited from a healthy
p a r e n t .I nt o t a l ,3de novo clinically significant CNVs
were identified in 3 out of the 82 patients (3.6%) and 11
abnormalities with uncertain clinical significance were
detected in 10 patients (12.2%). All three patients pre-
sented with CBM. Two patients were of subgroup c
(Background) associated with CBM and improvement
and one patient was of subgroup b associated with CBM
and no improvement after intervention. The median de
Vries score] of all 82 patients was 4.47 (range 0-9).
Discussion
Array-CGH has proven to be an important tool to detect
submicroscopic chromosomal aberrations. We used
DNA oligonucleotides to study 82 patients with normal
karyotype in whom a chromosomal abnormality was sus-
pected due to the combination of clinical features. All
82 patients presented with MR or LD, dysmorphic facial
features and congenital malformations. In order to better
define the clinical features correlated with chromosomal
imbalance, we divided the cohort in three subgroups.
a) 24/82 (29.3%) patients with MR/LD, facial dys-
morphism, congenital malformations not associated with
CBM,
b) 40/82 (48.8%) patients with MR/LD, facial dys-
morphism, congenital malformations associated with
CBM and no improvement of cognitive skills after
intervention,
c)18/82 (21.9%) patients with MR/LD, facial dysmorph-
ism, congenital malformations associated with CBM and
improvement of cognitive skills after intervention.
All patients showed a normal G-banded karyotype,
and in all of the cases telomere rearrangements had
been excluded by FISH or MLPA.
In the 82 patients, 14 chromosomal imbalances were
detected (~17%). Three of the observed chromosomal
aberrations were de novo and eleven aberrations were
inherited from one of the phenotypically normal par-
ents. The array-CGH results were confirmed by FISH
technique in all three de novo cases (Figure 1).
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Page 2 of 8The de novo triplication (Patient 1) in 18q is reported
here for the first time. It involves chromosome band
18q21.1 and it spans a region of about 5.8 Mb. It is
known that Edwards syndrome is mostly associated with
trisomy 18, however several individuals with partial tris-
omy of the long arm of chromosome 18 have been
reported. In these cases patients display manifestations
ranging from a relatively mild to a severe phenotype.
Table 1 Clinical information and array-CGH results in Greek children with unexplained mental retardation
Case/
no
Gender MR Array-CGH results Origin Estimated
size
Clinical Features
1 F Moderate tripl(18)(q21.1)
42,812 Mb-48,558 Mb
de novo 6 Mb maxillary hypoplasia, small jaw, prominent occiput, hypertelorism,
epicanthal folds, downward slanting palpebral fissures with sunken
eyes and long eyelashes.
Brain MRI scan suggested periventricular leukomalacia (PVL).
2 M Severe dup(10)(q11.1q11.21)
46,568 Mb-51,264 Mb
de novo 6 Mb corpus callosum hypoplasia, mild dilatation of subarachnoid areas
and frontotemporal atrophy, severe central hypotonia, ataxia,
triangular face, enlarged cranium cerebrale, bifid scrotum,
cryptorchidism, ulnar deviation of both elbows, deep palmar creases
of hands and feet and syndactyly of 2nd and 3rd toes bilaterally.
3 F Moderate del(2)(q31.2q31.3)
178,393 Mb-182,296 Mb
de novo 3,9 Mb severe hypotonia with microcephaly, Brain MRI scan showing dilated
lateral ventricles and diminishing white matter at the level of the
trigons bilaterally.
Speech limited to simple vocalization with lack of meaning. Her
overall developmental level was equivalent to 8 months, which
corresponds to a developmental quotient (D.Q.) = 30.
4 M Severe del(6)(p21.2)
38,420 Mb-38,554 Mb
paternal 135 kb mild dysmorphic facial features (epicanthial folds, hypertelorism and
auricle abnormalities)normal growth parameters severe mental
retardation DQ 45, behavioural disorders with autistic features. motor
disorder, hypotonia of central origin, brain malformation,(pituitary
cyst), no cognitive improvement after intervention
5 F Moderate dup(15)(q13.3)
29,809 Mb-30,298 Mb
maternal 0.5 Mb mild dysmorphic facial and body features, such as hrinolalia with
high-pitched voice, epicanthus, myopia, clinodactyly, and wide
internipple distance
6 F Moderate dup(20)(p11.21)
25,375 Mb-25,420 Mb
paternal 80 kb microcephaly, cleft palate, somatometric parameters below the 3
rd
centile, perimembranous ventricular septal defect, hyperopia,
prominent forehead, synorphrys, long eyelashes, bulbous nasal tip,
smooth philtrum, thin upper lip, hirsutism, and bilateral clinodactyly
of the 5
th finger
7 M Moderate dup(16)(q22.1)
68,390 Mb-68,534 Mb
maternal 150 kb dysmorphic facial features, motor disorder, epicanthus, hyperopia
8 M Moderate dup(16)(p11.2)
27,741 Mb -27,919 Mb
paternal 200 kb mild microcephaly and dysmorphic facial features, maxillary
hypoplasia, epicanthal folds, up-slanting palpebral fissures, long
eyelashes and hypertelorism, auricle abnormalities and his mouth
characterized by a long philtrum with gothic palate
9 F Severe del(1q)(31.3)
196,153 Mb-196,532 Mb
maternal 400 kb somatometric parameters below the 3
rd centile, mild dysmorphic
facial features, auricle abnormalities, developmental and motor delay
10 M Severe del(11)(q21)
94,602, Mb-95,086, Mb
paternal 500 kb multiple gestation (triplex-IVF), dysmorphic facial features, squint, flat
filtrum, frontal bossing, epicanthus, auricle abnormalities,
macrocephaly, fronto-temporal brain atrophy, motor disorder,
hypotonia of central origin, severe mental delay, severe behavioral
disorders
11 M Severe dup(17)(q25.1)
70,793 Mb-71,106 Mb
paternal 300 kb neonatal hypotonia, macrocephaly, dolicocephaly, mild dilation of
subarachnoid area, severe developmental and motor delay,
cryptorchidism, mild dysmorphic, facial features, epicanthus,
clinodactyly, short neck, large distance between nipples, short
vraxionas
12 M Moderate del(1)(p12)
118,688 Mb-119,490 Mb
paternal 800 Kb mild dysmorphic facial features, bulbous nose, short fingers,
clinodactyly, upward slanting palpebral fissures, moderate learning
difficulties, language delay with phonological problems and
stuttering
13 M Severe dup(3)(p14.1)
65,912 Mb-66,462 Mb
paternal 550 kb severe motor disorder (marked spastic tetraplegia), dysmorphic facial
features (prominent forehead, low-set ears, epicanthal folds, flat
philtrum, and long eyelashes), severe developmental delay as his
developmental level was equivalent to 5 months.
dup(22)(q13.1q13.2)
38,255 Mb-39,383 Mb
maternal 1.1 Mb
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Page 3 of 8Genotype-phenotype correlations have suggested that
duplication of regions (18)(q12.1q21.2) is critical for the
trisomy 18 phenotype [9,10], while the relationship
between duplication of the other 18q regions and men-
tal retardation, growth delay, and dysmorphism is less
clear. Our patient displayed only mild dysmorphic fea-
tures and speech delay. Only one other case with dupli-
cation in this area but in a much larger region has been
reported [11]. It concerns a 9 year-old boy with pro-
found MR and growth delay. This individual was diag-
nosed with a duplication involving (18)(q12.3q21.31),
which spans a region much wider than the one reported
here. Neither the boy nor the girl in our study display
the typical Edwards syndrome phenotype but both indi-
viduals share some clinical features like failure to thrive,
slanting palpebral fissures and ventricular septal defect.
The absence of seizures in our case and the difference
in severity of MR and growth delay are probably related
to the difference in the size of the duplicated region. It
is possible that the mild phenotype in our case is due to
the fact that the region does not include genes influen-
cing physical development, or that the triplication does
not alter significantly the expression pattern of the cor-
responding genes.
Proximal 10q duplication (Patient 2) is a well defined
but rare genetic syndrome [12-19]. This represents the
first case of partial proximal trisomy 10q characterized
by array-CGH (Figure 2). The typical profile of partial
proximal trisomy 10q syndrome includes postnatal
growth retardation, microcephaly, and mild to moderate
developmental delay. Frequent dysmorphic features are
prominent forehead, small deep-set eyes, epicanthus,
upturned nose, bow-shaped mouth, micrognathia, flat
and thick ear helices, and long slender limbs. In concor-
dance, our patient showed severe central hypotonia,
ataxia, triangular face, enlarged cranium cerebrale, bifid
scrotum, cryptorchidism, ulnar deviation of both elbows,
deep palmar creases of hands and feet, and syndactyly
of 2nd and 3rd toes bilaterally. It is noteworthy that the
pericentromeric region 10p11.2 to 10q11.2 has been
reported to contain unbalanced chromosomal abnormal-
ities without phenotypic consequences [20].
Deletions involving 2q31-q32 (Patient 3)( F i g u r e3 )
have been reported in more than 30 patients [21-26].
Most mutations, involving the 2q31 segment, comprised
the HOXD gene cluster which plays an important role
in limb development. In our case, the patient showed no
limb malformation as the deletion did not involve the
HOXD gene cluster.
Dual chromosomal duplication (Patient 13) is a rarely
reported genetic condition. To our knowledge this is the
first case of simultaneous duplication involving 3p14.1
and 22q13.1-q13.2. Pramparo et al. (2008) [27] identified
for the first time a 7 Mb duplication of (22)(q13.1q13.2)
in a 10-year-old girl with dysmorphic features (promi-
nent forehead, small low-set ears, hypertelorism,
epicanthal folds, small palpebral fissures, short philtrum,
and syndactyly), brain-MRI clinical findings (signal
abnormalities in the periventricular white matter, hypo-
plastic corpus callosum, under-rotated hippocampus on
the left and atrophic hippocampus on the right side),
moderate MR, and severely disorganized mood and beha-
vior with periodic manic episodes. The authors showed
that the duplication was the result of a maternal intra-
chromosomal insertion. The 7 Mb duplicated region is
gene-rich, carrying > 120 known genes and ~50 novel
transcripts, presumably including genes whose copy
number increase is most likely associated with the phe-
notypic features. Our patient’s chromosome 22 duplica-
tion is smaller in size (~1.1 Mb) but still contains 9 genes
Figure 1 FISH analysis for the confirmation of a-CGH results in the three de novo imbalances. A. In patient 1 the analysis performed
using BAC probes RP11-742D12 in 18q21.1 (triplicated), RP11-160B24 in 18q21.2 (normal) and RP11-704G4 in 18q23 (normal). B. In patient 2 it
was used BAC probe RP11-292F22 in 10q11.22 (duplicated) and cep10 probe (normal) C. Lastly in patient 3 BAC probes RP11-12N7 in 2q31.1
(normal) and RP11-358M9 in 2q31.3 (deleted) were applied.
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Page 4 of 8of known function (8 fully-sized and one partial gene
sequence at the proximal breakpoint). The clinical fea-
tures of our patient have common characteristics with
those of the patient published by Pramparo et al.( 2 0 0 8 ) ,
mainly with regard to malformations. We anticipate
that the ~1.1 Mb duplicated chromosome 22 region is
associated with the patient’s phenotype, while some
contribution from the 550 kb 3p14.1 duplication should
also be considered. The latter assumption is supported
by the fact that the chromosome 22 duplication alone
was detected in the phenotypically normal mother. It
cannot be excluded that the dual duplication in this
patient is causative for the patient’s phenotype, as also
suggested by the double hit model proposed recently,
Figure 2 Array-CGH profile of chromosome 10 showing an interstitial duplication (patient 2). A. The whole chromosome 10 view. B. The
enlarged view of the rearrangement as provided by Agilent Technologies, CGH Analytics 3.5.14. The proximal duplication breakpoint was
between 45,478 Mb and 46,578 Mb. The distal duplication breakpoint was between 51,264 Mb and 51,676 Mb. The overall size of the duplication
was about 4.8 Mb.
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Page 5 of 8saying that two events (two CNVs) act in concert to pro-
duce a more severe phenotype [28].
Nine other patients (Patients 4-12) with developmen-
tal delay and various clinical features were found to
have deletions or duplications inherited from one of the
parents (Table 1). The size of these chromosomal aber-
rations ranged between 80 kb and 500 kb. However,
none of those appears to be associated with the patients’
phenotype since they were inherited from a healthy
parent. Therefore, these CNVs can be classified as likely
benign [29,30] and the underlying causes for the abnor-
mal phenotypes remain unknown.
Methods
Patients
A total of 82 Greek children were referred to the
Department of Pediatrics, ‘’Aglaia Kyriakou’’ Children’s
Hospital, Athens for developmental assessment from
Figure 3 Array-CGH profile of chromosome 2 showing an interstitial deletion (average log2 ratio: -0.83) (patient 3). A. The whole
chromosome 2 view. B. The enlarged view of the rearrangement as provided by Agilent Technologies, CGH Analytics 3.5.14. The proximal
deletion breakpoint was between 178,370 Mb and 178,393 Mb, and the distal deletion breakpoint was between 182,296 Mb and 182,369 Mb.
The overall size of the deletion was about 3.9 Mb.
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Page 6 of 82007 to 2009. All patients were scored using a clinical
scoring system [8]. Ages varied between one and thir-
teen years, with a mean age of 4.9 years. A total of 46
boys and 36 girls were analyzed. All patients had normal
karyotype (G-banding analysis at resolution of 550
bands per haploid karyotype, ISCN 2005) and subtelo-
meric abnormalities determined by MLPA or FISH tech-
niques had been excluded. Written informed consent
was obtained from the parents of all patients.
DNA isolation
Blood samples with EDTA were collected from patients
and parents. DNA extraction was carried out using the
Qiagen QIAamp® DNA blood mini kit (QIAGEN, Valencia,
CA, USA).
Array-CGH
Array-CGH analysis was performed using 4 × 44 K, 2 ×
105 K and 4 × 180 K commercial arrays (Agilent Tech-
nologies, Santa Clara, CA, USA) according to the manu-
facturer’s instructions. This platform contains 60-mer
oligonucleotide probes spanning the entire human gen-
ome with an overall median probe spacing of 22 Kb
(19 Kb in Refseq genes). A sex-matched reference DNA
(NA10851, NA15510, Coriell Cell Repositories) has been
used for each subject tested. Previously reported benign
CNVs listed in the Database of Genomic Variants
http://projects.tcag.ca/variation/ were excluded from
further analysis. After hybridization, the arrays were
scanned in a dual-laser scanner (DNA Microarray Scan-
ner with Sure Scan High-Resolution Technology, Model
G2565CA, Agilent Technologies) and the images were
extracted and analyzed through Agilent Feature Extrac-
tion software (v10.5.1.1) and DNA Analytics software
(v4.0.73), respectively. Changes in test DNA copy num-
ber at a specific locus are observed as the deviation of
the log2ratio value from the value of 0 of at least three
consecutive probes. The quality of each experiment was
assessed by using a parameter provided by Agilent soft-
ware (QC metric) and on the basis of DNA quality.
Bioinformatics
Copy number changes identified in the samples were
compared to the Database of Genomic Variants http://
projects.tcag.ca/variation/ and also visualized by using
the UCSC Genome Browser website http://genome.ucsc.
edu/. The positions of oligomers refer to the Human
Genome March 2006 assembly (hg18).
FISH analysis
All three significant de novo aberrations were confirmed
by metaphase FISH using BAC clones (RP11-742D12,
RP11-160B24 and RP11-704G4 for patient 1, RP11-
292F22, RP11-463P17 and RP11-164N7 for patient 2
and RP11-12N7 and RP11-358M9 for patient 3) in the
same region as the deletions or duplications identified
by microarray analysis [31]. Metaphase chromosomes
were obtained from blood lymphocytes according to a
standard protocol [32].
MLPA analysis
MLPA analysis was carried out using P036 and P070
probes purchased commercially from MRC-Holland
(Amsterdam, Netherlands). The procedure was carried
out according to the manufacturer’s protocol. Briefly,
100 ng DNA was denatured at 98°C and hybridized
o v e r n i g h ta t6 0 ° Cw i t ht h eSALSA probe mix P036 and
P070. The next day, samples were treated with Ligase
65 for 15 min at 54°C. The reaction was stopped by
incubating the samples at 98°C for 5 min. Finally, the
amplification step was carried out using the SALSA
PCR FAM-labeled primers. The amplification products
were analyzed on an ABI 3130 Genetic Analyzer
(Applied Biosystems, Carlsbad, CA, USA) using 36 cm
capillaries and POP-7 polymer. The obtained data were
analyzed using Genemapper 4 Software. The final analy-
sis of the MLPA data was carried out using the Coffaly-
ser Software.
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